Please use this identifier to cite or link to this item:
Title: Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects
Authors: Lee, Kok-Onn 
Tian, Edmund Feng
Cai, Martin Hui
Wang, Hong
Chan, Yiong-Huak 
Sim, Meng-Kwoon
Keywords: Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Issue Date: 1-Mar-2018
Citation: Lee, Kok-Onn, Tian, Edmund Feng, Cai, Martin Hui, Wang, Hong, Chan, Yiong-Huak, Sim, Meng-Kwoon (2018-03-01). Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects. DRUGS IN R&D 18 (1) : 51-54. ScholarBank@NUS Repository.
Abstract: In an earlier single-dose escalation study to evaluate the safety and pharmacokinetics of orally administered des-aspartate-angiotensin I (DAA-I) in healthy subjects, the plasma level of DAA-I could not be determined because DAA-I is rapidly degraded in the circulation. The present study investigated the oral bioavailability of DAA-I by measuring the prostaglandin E2 metabolite (PGEM) in the plasma samples of the same trial. PGEM is a stable derivative of PGE2, which has been shown to be a biomarker of DAA-I. The data show that plasma from two of the three subjects who were orally administered the efficacious preclinical dose of 0.70 mg/kg DAA-I exhibited a significant PGEM peak at 5–6 h postdose. Plasma of subjects who were administered 0.08 and 1.5 mg/kg DAA-I, the subefficacious and two-times efficacious dose, respectively, did not exhibit a similar PGEM peak. This observation is concordant with the known in vivo actions of DAA-I, especially its hypoglycemic action where maximum efficacy occurred at a dose of 0.7 mg/kg, and decreased to nil at the two-times efficacious dose. The onset of the PGEM peak at 5–6 h postdose was closed to the 4-h onset of absorption of [C14]DAA-I seen in preclinical rat studies, albeit the absorption kinetics between rodents and humans are not identical. The occurrence of polymorphism of enzymes involved in the formation and degradation of PGE2 is common, and this has been attributed to contributing to the variation in response, onset and peak PGEM observed among the three subjects who were administered the efficacious dose.
Source Title: DRUGS IN R&D
ISSN: 11745886
DOI: 10.1007/s40268-017-0218-4
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects.pdfPublished version433.03 kBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.